Business Context and Reporting Period
This Form 8-K is filed by Dermata Therapeutics, Inc. (DRMA), a Delaware corporation and emerging growth company, with a reporting date of June 3, 2025. The filing addresses a change in the registrant's certifying accountant.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current period. However, it references historical audit reports for the years ended December 31, 2024, and 2023, which contained an explanatory paragraph regarding a going concern uncertainty.
Material Changes
- Accountant Merger: On June 3, 2025, the Company's independent registered public accounting firm, Moss Adams LLP, merged with Baker Tilly US, LLP.
- Successor Appointment: The Audit Committee approved the appointment of Baker Tilly US, LLP as the successor independent registered public accounting firm effective June 3, 2025.
- Audit History: There were no disagreements with Moss Adams regarding accounting principles, practices, or audit scope during the years ended December 31, 2024 and 2023, or the interim period through June 3, 2025.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management outlook. The primary risk factor reiterated is the going concern uncertainty noted in the prior audit reports for 2023 and 2024. No reportable events or disagreements requiring disclosure under Regulation S-K were identified during the relevant periods.
Investor Verification Checklist
- Verify the status of the going concern uncertainty previously disclosed in the 2023 and 2024 audit reports.
- Review the letter from Moss Adams LLP (Exhibit 16.1) to confirm their agreement with the statements regarding the change in accountant.
- Monitor future filings for the first audit report issued by the new firm, Baker Tilly US, LLP.
- Check for any subsequent updates on the Company's liquidity position given the prior going concern qualification.